Search - tctmd.com

Displaying 101 - 120 of 325

Sort: Relevancy | Date

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

Presentation SIF 2019

DEBATE:What is the Optimal Choice for Post PCI Patients Requiring Chronic Anticoaguation :Triple Therapy

Presenter: Michael A. Kutcher

March 29, 2019

Presentation SIF 2019

Dual vs. Triple Therapy Post PCI Is There Really Any Debate?

Presenter: Jeffrey A Southard

March 29, 2019

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Caitlin E. Cox

March 17, 2019

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

Todd Neale

January 29, 2019

News Daily News

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

Yael L. Maxwell

December 13, 2018

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Todd Neale

October 03, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

Is There Still a Role for Triple Therapy Based on Recent Studies?

Presenter: Walter Desmet, Guy J. Friedrich

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

Presentation TCT 2018

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

Presenter: Jeroen J. Bax, Stephan Windecker

September 21, 2018

News Conference News ESC 2018

FFRCT Shifts Patient Management, Linked to Better 90-Day Outcomes: ADVANCE Registry

Caitlin E. Cox

September 07, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

Advertisement

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

DEBATE:What is the Optimal Choice for Post PCI Patients Requiring Chronic Anticoaguation :Triple Therapy

Dual vs. Triple Therapy Post PCI Is There Really Any Debate?

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Is There Still a Role for Triple Therapy Based on Recent Studies?

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

FFRCT Shifts Patient Management, Linked to Better 90-Day Outcomes: ADVANCE Registry

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content